Mainstay Medical reports $6.35M losses in 1st half of 2015: 5 key notes

Spinal Tech

Mainstay Medical reported its financial results for the first six months of 2015.

Here are five key notes:

 

1. The group incurred $6.35 million in losses to date and as of June 30, the group reported shareholders' equity of $11.4 million and cash of $12.5 million. The company expects to incur further losses in the coming quarters while in the pre-revenue stage in the development of ReActiv8.

 

2. The company reported research and development costs at $1.2 million during the first half of the year. Clinical and regulatory expenses related to the ongoing ReActiv8 –A Clinical Trial and regulatory activities were $2.3 million.

 

3. Operating expenses were $6.3 million during the first half of the year. Cash on hand was totaled at $12.5 million and operating cash flows for the period ended June 30 were $5.7 million.

 

4. The company closed debt financing for up to $15 million on Aug. 24, 2015. The secured debt facility is non-dilutive to existing shareholders and is provided by IPF Partners.

 

5. Positive clinical results for the ReActive8-A Clinical Trial were announced recently. In July and August, the company was issued three new U.S. patents.

 

More articles for orthopedic devices:
ECM Medcial to distribute Vertebral Technologies' Interfuse System in China
MIS SI joint fusion: Are outcomes positive? 10 things to know on 3 new studies
Amedica releases lumbar interbody spinal fusion device

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers